PDCD1 and melanoma: Serratì et al. demonstrated that patients who do not respond to ICI therapy may have higher levels of PD-L1+EV and PD-1+EV (from tumor cells and immune cells, respectively), so they can serve as two predictive biomarkers for melanoma immunotherapy[158].